CONMED Announces Planned CFO Transition and Successor Search

Conmed ( (CNMD) ) has issued an announcement.

On January 8, 2026, CONMED Corporation announced that Chief Financial Officer Todd Garner will separate from his CFO role effective on the earlier of March 15, 2026, or the appointment of a new permanent CFO, as the company initiates a comprehensive external search for his successor. The company emphasized that Garner’s departure is not due to any disagreement over operations, policies, financial results, or accounting practices, and detailed a transition arrangement under which he will remain with CONMED through November 2, 2026 in a consulting capacity, continue to receive his current base salary, remain eligible for certain cash bonuses and benefits, and have his outstanding equity awards continue to vest through the end of the consulting period, underscoring a structured and orderly leadership transition for financial stakeholders.

The most recent analyst rating on (CNMD) stock is a Hold with a $44.00 price target. To see the full list of analyst forecasts on Conmed stock, see the CNMD Stock Forecast page.

Spark’s Take on CNMD Stock

According to Spark, TipRanks’ AI Analyst, CNMD is a Neutral.

Conmed’s overall stock score reflects strong financial performance and strategic initiatives aimed at long-term growth. However, bearish technical indicators and challenges in maintaining profit margins weigh on the score. The strategic shift in capital allocation and positive corporate governance changes provide additional support.

To see Spark’s full report on CNMD stock, click here.

More about Conmed

CONMED Corporation is a medical technology company that develops and markets surgical and patient care devices, with a focus on serving hospitals and healthcare providers in the global medical equipment industry.

Average Trading Volume: 524,763

Technical Sentiment Signal: Sell

Current Market Cap: $1.35B

For a thorough assessment of CNMD stock, go to TipRanks’ Stock Analysis page.